Who we are 

 

Our team covers a wide and diverse set of disciplines spanning from medicinal chemistry to biomedical engineering, computer science and business development, among others.

Board Members and Scientific Advisors, in turn, bring a great depth and breadth of experience in scientific leadership and management capabilities to Mind the Byte. Collectively, we are committed to provide a first-in-class service and contribute to the company’s growth and vision.

BOARD OF DIRECTORS


Alfons Nonell-Canals, PhD

Founder & Chief Executive Officer (CEO)

Alfons is a specialist in Computer-Aided Drug Design, in the development of such software, and in large-scale chemical and biological analyses. He holds a PhD in Computational Chemistry and after some post-doc sessions, he decided to establish Mind the Byte to achieve the synergy between his experience and modern AI and cloud computing techniques.

 

Albert Garcia Pujadas

Co-founder & CEO of Foxize School

Business professional with extensive experience in the fields of marketing and technology. Professor and academic coordinator of the Master’s in Direct and Digital Marketing of the UPF Barcelona School of Management since 2005. Previously, he founded Ogilvy Interactive Spain and held executive positions at Nikodemo, eresMas and Intercom.


Xavier Castells, MBA

CFO of Inkemia IUCT Group

Chief Financial Officer of InKemia IUCT Group, a biotechnology group listed on the Alternative Investment Market, and head of the IUCT Emprèn capital investment fund. He holds a Bachelor’s Degree in Business Administration, an MBA from ESADE and a Master’s in International Management from the Thunderbird School of Global Management (Arizona).


Marta Príncep, PhD

Director of the Technology Dept of Bellavista

She holds a PhD in Biology, is a graduate of ESADE’s Advanced Management Programme and of the ‘Global growth strategy, business opportunities and financial challenges’ programme of the University of Pennsylvania. She has over 20 years’ experience in executive positions in the field of life science.


Peter Edman, Prof

Scientific Advisor & Board Member

He has been working in the pharma industry for decades, where he has held a number of senior positions within Orexo, Sobi, Biovitrum, Pharmacia, Astra and AstraZeneca. He has also been Professor at the University of Uppsala (Sweden). Nowadays, he is acting as an independent scientific advisor and board member to companies within the life science sector.

 

Oriol Segarra, MBA

CEO of Uriach

He has an extensive background in strategic and management positions in the pharmaceutical sector, including COO at Synthon. He holds an MBA from ESADE and has also attended postgraduate courses at Stanford, Harvard and IESE. As CEO of Uriach, he has led the change of the company from a family firm to a successful transnational corporation.

MANAGEMENT TEAM


Alfons Nonell-Canals, PhD

Founder & Chief Executive Officer (CEO)

Alfons s is a specialist in Computer-Aided Drug Design, in the development of such software, and in large-scale chemical and biological analyses. He holds a PhD in Computational Chemistry and after some post-doc sessions, he decided to establish Mind the Byte to achieve the synergy with his experience and modern AI and cloud computing techniques.


Melchor Sanchez Martinez PhD

Scientific Director

PhD in theoretical and computational chemistry applied to the uderstanding of biological and chemical systems towards drug design. In Mind the Byte he is in charge of carrying out client consultancy and R&D projects. He is also course instructor at the Open University of Catalonia, where he assesses students of the MSc in Bioinformatics & Biostatistics.


Thomas Högberg, Assoc Prof

Chief Strategy Officer (CSO)

Over 45 years in the pharma industry with experience from big pharma to biotech where he headed various departments and had leading roles from early drug discovery to marketed products in several therapeutic areas and been engaged in business development. He has published >100 papers and is the co-inventor on >50 patent applications.

David Vidal, PhD

R&D Director

David has over 10 years of experience in computational drug discovery, with a strong focus on the design, development and integration of in silico tools for drug design, screening, target profiling and ADME modeling. As R&D director, he has the global objective of upgrading and consolidating company’s drug discovery SaaS platform.

Claudia Nieva Boza, PhD

Project Management Director

PhD pharmacist with ten years’ experience in research, including postdoctoral positions in Germany and Spain in fields related to developmental and cancer biology and diagnostics. After her academic career, she has held several positions in the area of business development and technology transfer.

ADVISORY BOARD


Thomas Högberg, Assoc Prof

Chief Strategy Officer (CSO)

Over 45 years in the pharma industry with experience from big pharma to biotech where he headed various departments and had leading roles from early drug discovery to marketed products in several therapeutic areas and been engaged in business development. He has published >100 papers and is the co-inventor on >50 patent applications.

Peter Edman, Prof

Scientific Advisor & Board Member

He has been working in the pharma industry for decades, where he has held a number of senior positions within Orexo, Sobi, Biovitrum, Pharmacia, Astra and AstraZeneca. He has also been Professor at the University of Uppsala (Sweden). Nowadays, he is acting as an independent scientific advisor and board member to companies within the life science sector.